Publication | Closed Access

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

Phase-iii StudyAutoimmune DiseaseImmunologyClinical TrialsClinical DermatologyChronic Plaque PsoriasisDermatologyExperimental DermatologyImmunotherapyMedicine